Core Viewpoint - The Medical Health R Index (480016) experienced a decline of 1.42% on December 15, closing at 7247.38 points, with a total transaction volume of 21.207 billion yuan and a turnover rate of 0.7% [1] Group 1: Index Performance - On the same day, 12 out of the index's constituent stocks rose, with Tongrentang leading at a 2.38% increase, while 35 stocks fell, with Zaiqing Pharmaceutical leading the decline at 8.6% [1] - The net outflow of main funds from the index's constituent stocks totaled 917 million yuan, while retail investors saw a net inflow of 676 million yuan [1] Group 2: Constituent Stocks Details - The top ten constituent stocks of the Medical Health R Index are as follows: - Zaiqing Pharmaceutical (sh688266) with a market cap of 26.471 billion yuan, down 8.6% - Sanofi (sh688336) with a market cap of 37.439 billion yuan, down 5.83% - Dize Pharmaceutical (sh688192) with a market cap of 26.998 billion yuan, down 5.73% - Shenzhou Cell (sh688520) with a market cap of 19.884 billion yuan, down 4.08% - Xinlitai (sz002294) with a market cap of 62.987 billion yuan, down 3.75% - Kanglong Chemical (sz300759) with a market cap of 51.301 billion yuan, down 3.54% - East China Pharmaceutical (sz000963) with a market cap of 70.231 billion yuan, down 3.40% - WuXi AppTec (sh603259) with a market cap of 272.148 billion yuan, down 3.02% - Hengrui Medicine (sh600276) with a market cap of 407.391 billion yuan, down 3.00% - Kyoto Biopharmaceuticals (sz002653) with a market cap of 59.423 billion yuan, down 3.00% [1] Group 3: Fund Flow Details - The fund flow details for the constituent stocks indicate that: - Ziyun Mountain (600332) had a main fund net inflow of 79.604 million yuan - Tongrentang (600085) had a main fund net inflow of 61.288 million yuan - Pianzai Slimming (600436) had a main fund net inflow of 38.587 million yuan - Zaiqing Pharmaceutical (688266) had a main fund net inflow of 25.856 million yuan - The overall trend shows a significant net outflow from retail investors across various stocks [2] Group 4: Index Adjustment - On December 15, 2025, the Medical Health R Index underwent adjustments, adding four new stocks: - Sanofi (688336) with a market cap of 37.439 billion yuan - Dize Pharmaceutical (688192) with a market cap of 26.998 billion yuan - Changshan Pharmaceutical (300255) with a market cap of 62.230 billion yuan - Kanghong Pharmaceutical (002773) with a market cap of 27.907 billion yuan - Four stocks were removed from the index, including Jianyou Co. (603707) and Tongce Medical (600763) [3]

Core Insights - The average stock price on the STAR Market is 40.75 yuan, with 71 stocks priced over 100 yuan, and the highest priced stock is Cambrian-U at 1331.90 yuan [2][3] - A total of 172 stocks increased in price while 416 stocks decreased, with the average decline for stocks over 100 yuan being 3.16% [2][3] - The premium of stocks over their issue prices averages 498.01%, with notable premiums for companies like Shunwei New Materials and Cambrian-U [2][3] Stock Performance - Cambrian-U closed at 1331.90 yuan, down 0.90%, followed by Moer Thread-U at 764.90 yuan and SourceJet Technology at 633.00 yuan [2][3] - Among the stocks priced over 100 yuan, 10 stocks saw an increase, with the largest gainers being Zhenray Technology, Haooubo, and Jingfeng Mingyuan [2][3] - The sectors with the highest concentration of stocks over 100 yuan include electronics, pharmaceuticals, and computers, with 38, 9, and 8 stocks respectively [2][3] Capital Flow - The net outflow of main funds from stocks over 100 yuan totaled 4.123 billion yuan, with Zhenray Technology, Zhongwei Company, and Anji Technology seeing the highest net inflows [3] - The total margin balance for stocks over 100 yuan is 95.915 billion yuan, with Cambrian-U, Zhongxin International, and Haiguang Information having the highest margin balances [3] Detailed Stock List - A detailed list of stocks over 100 yuan includes Cambrian-U, Moer Thread-U, and SourceJet Technology, with their respective closing prices and percentage changes [4][5]

以最新收盘价计算，A股平均股价为13.60元，其中股价超过100元的有161只，相比上一个交易日减少6 只。 百元股作为判定市场热度的信号之一，历来受到投资者关注。证券时报·数据宝统计显示，截至12月15 日收盘，沪指报收3867.92点，下跌0.55%，A股平均股价为13.60元，个股股价分布看，股价超过100元 的有161只，股价在50元至100元的有415只，股价在30元至50元的有735只。 股价超百元个股中，收盘价最高的是贵州茅台，今日报收1426.00元，上涨0.38%，其次是寒武纪、摩尔 线程等，最新收盘价分别为1331.90元、764.90元。 市场表现方面，收盘股价超百元股中，今日平均下跌2.39%，跑输沪指1.84个百分点。今日上涨的有32 只，涨幅居前的有臻镭科技、飞沃科技等，下跌的有128只，跌幅居前的有品茗科技、芯原股份等。 追溯发现，最新百元股近一个月平均上涨6.86%，其间沪指下跌3.07%，涨幅居前的有飞沃科技、超捷 股份、德科立等，涨幅分别为135.98%、108.57%、77.99%，今年以来平均涨幅为121.28%，强于沪指 105.88%，累计涨幅居前的有上纬新材、天普 ...

Core Insights - The average stock price of A-shares is reported at 13.60 yuan, with 34 stocks priced below 2 yuan, the lowest being delisted Suwu at 0.37 yuan [1][2] - The Shanghai Composite Index closed at 3867.92 points, indicating a relatively low representation of both high-priced and low-priced stocks in the A-share market [1][2] Low-Priced Stocks Overview - Among the low-priced stocks, 34 are priced below 2 yuan, with 9 of them classified as ST stocks, accounting for 26.47% of this group [1] - The stocks with the highest daily increase include *ST Lifan (up 2.80%), Jiugang Hongxing (up 1.23%), and HNA Holding (up 1.16%) [1] - The stocks with the largest daily decline include delisted Suwu (down 9.76%), *ST Yunwang (down 4.81%), and *ST Huifeng (down 3.57%) [1] Detailed Low-Priced Stock Data - The table lists various low-priced stocks, including their latest closing prices, daily change percentages, turnover rates, and industry classifications [1][2] - Notable stocks include: - Delisted Suwu: 0.37 yuan, -9.76% change, 5.49% turnover, in the pharmaceutical industry - *ST Lifan: 1.47 yuan, +2.80% change, 10.37% turnover, in the computer industry - *ST Jinke: 1.48 yuan, +0.68% change, 0.65% turnover, in the real estate sector [1][2]

Investment Rating - The industry is rated as "Overweight," indicating an expected increase in performance exceeding the market benchmark index by more than 10% over the next 6-12 months [39]. Core Insights - The North Exchange market has shown a significant recovery, with the average daily trading volume of all A-shares reaching 19.51 billion yuan, a week-on-week increase of 40.6%. The North Index 50 rose by 2.79% during the same period [1][7]. - Key stocks that performed well include Tianli Composite (up 117.2%), Dapeng Industrial (up 51.1%), and Chicheng Co. (up 40.7%). Conversely, stocks with the largest declines included *ST Guandao (down 77.2%) and Hongxi Technology (down 12.4%) [1][16]. - Recent policy developments, including a meeting of the Central Political Bureau focusing on economic work for 2026 and the announcement allowing Nvidia to sell H200 chips to China, are expected to influence market sentiment positively [1][19][23]. Summary by Sections Market Overview - The North Exchange's average daily trading volume reached 19.51 billion yuan, marking a 40.6% increase from the previous week. The North Index 50 saw a rise of 2.79%, with an average turnover rate of 2.6% [1][7][34]. Key News and Policies - The Central Political Bureau's meeting emphasized the importance of economic stability and growth for 2026, while the U.S. government's policy shift regarding AI chip sales to China is expected to impact market dynamics positively [19][23]. Core Driving Factors - The macroeconomic environment has improved, with the Federal Reserve's interest rate cut and domestic policies focusing on enhancing capital market functions. This has led to increased risk appetite among investors [32][33]. - The performance of new stocks has been strong, with significant interest in newly listed companies, indicating a healthy market for initial public offerings [33]. Investment Recommendations and Strategies - Future investment strategies should focus on three areas: the value of weight stocks in the North Index 50, companies with strong performance and R&D investment, and sectors benefiting from policy support such as commercial aerospace and humanoid robots [2][35].

一周观点 总量研究 本周观点 | 总量研究 2 | | --- | | 本周观点 2 | | 重点报告 2 | | 行业研究 4 | | 本周观点 4 | | 重点报告 5 | | 公司研究 6 | | 重点报告 6 | | 重点报告摘要 7 | | 总量研究 7 | | 行业研究 10 | | 公司研究 12 | | 领域 | 一周观点 | 分析师 | | --- | --- | --- | | | 新一轮政策部署护航，A 股跨年行情可期。一方面，未来国内经济政策有望持续发力，经济增 | | | | 长有望保持在合理区间，进一步夯实资本市场繁荣发展的基础；另一方面，政策红利释放，有 | | | 策略 | 望提振市场信心，进一步吸引各类资金积极流入；此外，历史来看，"十三五"和"十四五" | 张宇生 | | | 开局之年 A 股市场均有不错的表现，历史上开局之年的积极表现有望在 2026 年得到延续。 | | | | 本周国内权益市场指数普遍上涨，创业板指上涨 1.86%,周期主题基金表现占优，消费、医药 | | | 金工 | 主题基金净值回调。国内市场新成立基金 39 只，合计发行份额为 365.89 亿份 ...

经历了2021至2023年的持续三年低迷行情后，2024年以来港股市场已迈入"业绩+估值"双击的行情。 年初受大模型推出及AI商业化落地催化，中国资产重估行情启动，港股市场领衔上行，虽然四季度以 来港股市场有望承压，但年初至今的累计涨幅仍然亮眼，在全球主流市场指数中名列前茅，成功逆袭！ 恒生指数涨29.6%，其中的港股通标的更是"青出于蓝胜于蓝"，恒生港股通指数涨幅高达34.6%！ 今日，跟踪恒生港股通指数的恒生港股通ETF（520820）重磅上市！恒生港股通ETF（520820）囊括港 股重点板块稀缺资产，轻松布局港股互联网、创新药、新消费等优质龙头！ 数据截至2025.12.14 那么历经两年的估值修复后，港股市场在2026年又将有何表现呢？"指数投资"趋势下，又有哪些新工具 值得关注呢？ 【春山可望？2026年港股研判："乘势而上、迈向新高度"】 中信证券从多个维度剖析了港股市场2026年的配置价值，其中指出： 估值维度，当前港股仍是全球主要市场中的估值洼地，而计算当前的恒生指数ERP仍高达到5.7%。业绩 来看，当前Bloomberg一致预期显示恒生指数的2026E净利润同比增长8.5%。随着港股基本 ...

Core Viewpoint - The Shenzhen Stock Exchange and Shenzhen Securities Information Co., Ltd. announced a periodic adjustment of sample stocks for various indices, including the Shenzhen Component Index and ChiNext Index, effective December 15, 2025 [2][5]. Group 1: Index Adjustments - The Shenzhen Component Index will replace 17 sample stocks, including 7 from the main board and 10 from the ChiNext [5][6]. - The ChiNext Index will replace 8 sample stocks [5]. - The Shenzhen 100 Index will replace 7 sample stocks, with 4 from the main board and 3 from the ChiNext [5][7]. - The ChiNext 50 Index will replace 5 sample stocks [5]. Group 2: Industry Weightings - After the adjustments, the strategic emerging industry weight in the ChiNext Index will be 93%, while the ChiNext 50 Index will have a weight of 98%, with new generation information technology industries like AI, chips, and optical modules accounting for 45% [3][10]. - The Shenzhen 100 Index will see an increase in the weight of strategic emerging industries to 81%, with advanced manufacturing, digital economy, and green low-carbon sectors reaching 79% [10]. Group 3: Company Performance - The new sample companies in the ChiNext Index reported a 13% year-on-year increase in R&D expenses, with R&D expenses accounting for 5% of operating income, and 30 companies having an R&D intensity exceeding 10% [10]. - The new sample companies in the ChiNext Index experienced a 16% increase in operating income and a 24% increase in net profit year-on-year, with high-end equipment manufacturing and new energy sectors seeing net profit growth of 60% and 54%, respectively [10][11]. - The Shenzhen 100 Index companies have expanded their business internationally, with over 80% of sample companies operating in global supply chains, and overseas revenue showing a compound annual growth rate of 17% over the past three years [10].

来源：市场资讯 （来源：华泰证券策略研究） 目前市场下行空间可控但上行胜率尚未打开。港股情绪指标依然处于悲观区间，对应磨底阶段，情绪指 数走势与2024年11月类似。彼时情绪指标进入恐慌区间后，市场在2025年初迎来明显反弹，春节前后 DeepSeek催化下斜率放大。未来行情催化因素可能来自以下三点预期差：1）人民币升值：升值共识一 旦形成，资本流动或发生重要改变，可以类比今年欧洲市场；2）企业出海：市场依然担忧汇率升值和 出口高基数的影响，明年上半年中美关系依然处于温和期，出口韧性存在预期差；3）国内科技进展突 破，走出独立路径等。配置层面，短期关注资金面供需改善后的弹性品种如科技和医药，中期依然建议 成长+顺周期均衡，切换时间在二季度左右。全年维度看，个股相关性下降，去伪存真、自下而上的α 机会更加重要。 回顾：港股表现弱于A股，南向疲软、情绪基数和行业分化是主因 近期投资者普遍感受到港股表现相对疲软。10月至今MSCI香港/沪深300/恒生指数/纳斯达克金龙指数涨 跌幅分别为2.2%/-0.7%/-3.3%/-10.3%（均以港币计价），市场表现的表观差异并不如体感大。归因来 看： 1）10月初至今，作 ...

Fixed Income - The central economic work conference indicates a continuation of moderately loose monetary policy, suggesting that the current environment remains conducive to rate cuts and reserve requirement reductions [2][10] - The net financing scale of government bonds in 2026 is expected to slightly increase to around 14.5 trillion yuan, maintaining a stable issuance without significantly increasing supply pressure [10][12] - Social financing growth is projected to decline to approximately 7.3% in 2026, with a total increment of around 34 trillion yuan [10][12] - The bond market in 2026 may perform better than expected, with a potential policy interest rate cut of about 20 basis points anticipated [12][18] Pharmaceutical Industry - The collagen market shows significant potential, with animal-derived products having distinct advantages; Baijin Medical has three types of animal collagen products, with the first type recently approved [4][23] - The domestic market for animal-derived collagen in functional skincare and medical dressings is projected to reach 243 billion yuan by 2027 [23] - Baijin Medical is expected to submit 12 product registrations this year, with ongoing product launches anticipated, driving long-term growth [4][23] New Consumption - The CPI in November increased by 0.7%, primarily driven by rising food prices, marking the highest growth since March 2024 [28][29] - Lin Qingxuan, a high-end domestic skincare brand, reported a revenue of 1.052 billion yuan in the first half of 2025, reflecting a year-on-year growth of 98.3% [29][30] - The company has a strong offline presence with 554 stores, over 95% of which are located in shopping malls, positioning it as a leader among domestic and international high-end skincare brands [29][30] Metal New Materials - The Federal Reserve's recent rate cut of 25 basis points has led to an increase in copper prices, with expectations of a supply-demand shift towards a shortage in the future [32][33] - The lithium market is experiencing strong demand, with lithium prices entering an upward cycle due to ongoing inventory depletion [35] - Cobalt prices are expected to continue rising due to a tight supply situation, with recent changes in export regulations from the Democratic Republic of Congo impacting the market [36] North Exchange - The recent adjustments to the North Exchange 50 and specialized indices are expected to enhance the quality and scale of listed companies, with a focus on performance and strong growth potential [39][40] - The market is showing signs of stabilization, with an emphasis on identifying undervalued assets and companies in strong growth sectors such as commercial aerospace and AI [40]